• EPZ5676: Potent DOT1L Inhibitor for MLL Leukemia Research

  2026-05-12

  EPZ5676 is a potent and selective DOT1L inhibitor that disrupts H3K79 methylation, showing nanomolar efficacy in acute leukemia cell lines with MLL translocations. Its high selectivity profile and robust in vivo activity make it a critical tool for epigenetic and leukemia research.

• UBC9 Controls PINK1 SUMOylation to Mitigate Parkinson’s Dise

  2026-05-12

  This study uncovers a pivotal role for UBC9 in regulating mitophagy and oxidative stress in Parkinson’s disease by facilitating SUMOylation of PINK1. The work provides mechanistic insight into neuroprotective pathways and highlights new experimental approaches for dissecting protein interactions in disease models.

• Biomimetic Chromatography for Pulmonary Drug Permeability Mo

  2026-05-11

  This study pioneers a comparative evaluation of two biomimetic chromatography techniques—immobilised artificial membrane liquid chromatography (IAM-LC) and open-tubular capillary electrochromatography (OT-CEC)—coupled with mass spectrometry, for assessing lung permeability of pharmaceuticals. The findings clarify the strengths and contextual performance of each method, with implications for high-throughput permeability screening in drug development.

• Pseudouridine Mapping and High-Yield RNA Synthesis: HyperScr

  2026-05-11

  Discover how the HyperScribe T7 High Yield RNA Synthesis Kit advances RNA research by enabling precise in vitro transcription, including the synthesis of modified RNAs for epitranscriptomic mapping. Explore unique insights on pseudouridine detection and workflow optimization.

• EZ Cap™ Cas9 mRNA (m1Ψ): Cap1-Capped mRNA for Genome Editing

  2026-05-10

  EZ Cap™ Cas9 mRNA (m1Ψ) offers a Cap1-capped, N1-Methylpseudo-UTP–modified mRNA designed for high-fidelity genome editing using the CRISPR-Cas9 system. The Cap1 structure and m1Ψ modification synergistically increase translation efficiency and mRNA stability while suppressing innate immune activation. This product from APExBIO is engineered for reliable, reproducible genome editing in mammalian cells.

• JNK-IN-7: Selective JNK Inhibitor for Advanced MAPK Research

  2026-05-09

  JNK-IN-7 empowers researchers to dissect MAPK signaling and apoptosis with unmatched selectivity, translating recent advances in cell death and innate immunity into actionable workflows. This guide delivers evidence-based protocols, troubleshooting strategies, and key insights from cutting-edge reference studies.

• Super-Enhancer-Driven KLF6 Regulates Adipogenesis in hADSCs

  2026-05-09

  Nguyen et al. elucidate how a super-enhancer (SE_00159) upregulates KLF6 expression to drive adipogenic differentiation in human adipose-derived stem cells (hADSCs). Their integrative approach reveals a PPARγ/p300-eRNA axis and highlights KLF6-mediated repression of DLK1, providing new mechanistic insight into obesity-linked adipogenesis.

• Necrostatin-1: Strategic RIP1 Inhibition for Translational S

  2026-05-08

  Explore the mechanistic depth and translational promise of Necrostatin-1 (Nec-1), a selective RIP1 kinase inhibitor, as a pivotal tool for necroptosis research and disease modeling. This thought-leadership piece delivers practical assay guidance, strategic insights for acute kidney injury (AKI) and inflammatory models, and a forward-looking perspective anchored in both current literature and emerging cross-talk between cell death pathways. Researchers will gain actionable protocol parameters and a nuanced view of Nec-1’s value within the competitive landscape—transcending standard product content.

• Systematic In Vivo Analysis of Ibotenic Acid Neurotoxicity i

  2026-05-07

  This study systematically characterizes the dose- and time-dependent neurotoxic effects of ibotenic acid in a murine model, providing robust behavioral, biochemical, and neuronal injury markers. These findings offer foundational toxicological data for neuroscience research and inform future protocols using ibotenic acid as a neurodegenerative disease model.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Applied Workflows

  2026-05-07

  Digoxin’s dual utility in cardiac and antiviral research makes it indispensable for translational studies targeting the Na+/K+ ATPase pump. This guide details optimized experimental workflows, highlights cell-type specificity in antiviral assays, and offers troubleshooting strategies for robust, reproducible results.

• Estradiol Benzoate: Mechanistic Precision in Estrogen Recept

  2026-05-06

  Explore how Estradiol Benzoate, a potent estrogen receptor alpha agonist, enables high-fidelity hormone receptor research. This article delivers a deeper mechanistic analysis, practical assay guidance, and comparative insights beyond standard protocols.

• Toremifene in Breast Cancer: 20 Years of Clinical Evidence

  2026-05-06

  This review synthesizes two decades of clinical data on toremifene, a selective estrogen receptor modulator, in the treatment of estrogen receptor-positive breast cancer. The findings inform personalized therapy strategies and highlight the role of molecular profiling in optimizing patient outcomes.

• Cyclopamine as a Hedgehog Signaling Inhibitor: Optimized Use

  2026-05-05

  Cyclopamine enables precise Hedgehog pathway inhibition for cancer research and teratogenicity modeling, offering robust, literature-backed workflows with quantifiable endpoints. This guide details actionable protocols, advanced applications, and troubleshooting grounded in recent experimental and epigenetic research advances.

• Meropenem: Applied β-Lactam Carbapenem Workflows & Troublesh

  2026-05-05

  Leverage Meropenem’s ultra-broad-spectrum action for advanced antibacterial research across Gram-negative and Gram-positive models. Discover protocol enhancements, troubleshooting strategies, and comparative insights that drive reproducibility and resistance modeling in the evolving landscape of septicemia and carbapenem-resistant infections.

• FLOT1-FOSL2 Interaction Drives Microglial Polarization in AD

  2026-05-04

  This study uncovers how the interaction between FLOT1 and FOSL2 upregulates EphA2 transcription, activating the p38/MAPK pathway and shifting microglia toward a pro-inflammatory state in Alzheimer's disease. These mechanistic insights highlight a novel regulatory axis with therapeutic potential for modulating neuroinflammation and cognitive decline in AD models.

16241 records 1/1083 page Next 12345 下5页 Last page